Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04659629
Recruitment Status : Active, not recruiting
First Posted : December 9, 2020
Last Update Posted : December 2, 2022
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Neoleukin Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : December 2024
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 6, 2023